Thursday, November 19, 2026

New evidence questions benefits of turmeric for knee arthritis

 A new Cochrane review has found that turmeric supplements may provide little or no clinically important pain relief for people with knee osteoarthritis, challenging conclusions from earlier research that suggested a benefit.

Osteoarthritis is a complex joint disease and the most common type of arthritis. While treatments such as exercise and medication can help manage symptoms, there is currently no cure.

Turmeric, a common culinary spice, contains compounds known as curcuminoids, including curcumin, which have anti-inflammatory properties. Because inflammation contributes to osteoarthritis symptoms, turmeric supplements have attracted considerable interest as a potential treatment.

Doubt cast over benefits of turmeric for arthritis

An international group of researchers examined 9 studies including 1,245 people with knee osteoarthritis. The studies compared turmeric supplements with placebo, non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and diclofenac, and paracetamol.

The studies investigated a range of turmeric extracts and curcuminoid-based products. The products differed in their composition, curcuminoid content and dosage.

Participants were aged between 52 and 62 years on average, around two-thirds were women, and the studies were conducted in Australia, Belgium, India and Thailand. The trials were relatively short, lasting between four weeks and three months.

Overall, the current evidence does not demonstrate a clear clinical benefit. Compared to placebo and anti-inflammatory drugs, turmeric was not shown to be more effective. However, the available evidence remains uncertain due to limitations in the underlying studies.

Dr Ivan Shirinsky, lead author of the review and a practicing rheumatologist, says: "As a clinician and researcher, I am not surprised by these findings. Osteoarthritis is a complex and still incompletely understood disease. Despite intensive research, effective pharmacological treatment options remain limited, and many promising approaches have yielded limited or inconclusive evidence of clinical benefit. A better understanding of the mechanisms underlying osteoarthritis may help us develop more effective treatments in the future."

Why checking the trustworthiness of clinical trials matters

Previous systematic reviews generally suggested that turmeric may improve pain and physical function in people with osteoarthritis. However, some of these findings may have been influenced by studies whose trustworthiness had not been formally assessed.

The new Cochrane review incorporated formal assessments of trial trustworthiness, providing an additional safeguard when evaluating the available evidence. Notably, 10 trials raised concerns during trustworthiness screening and were placed in the awaiting classification category pending clarification from their authors. These trials were not included in the analyses because the concerns remained unresolved.

The authors note that earlier reviews often included a wider range of studies, including trials based only on radiographic diagnoses of osteoarthritis, non-oral turmeric preparations, or curcumin products combined with other active ingredients. Earlier reviews also did not apply the same trustworthiness screening procedures. Differences in study selection and methodology, including the assessment of trial trustworthiness, may help explain why the new Cochrane review reached more cautious conclusions than previous reviews.

“This review highlights the importance of assessing the trustworthiness of clinical trials,” adds Dr Shirinsky. “Such assessments help identify studies that require further clarification before their findings can be used to inform conclusions about treatment effects.”

Asked whether he would recommend turmeric supplements to patients with knee osteoarthritis, Dr Shirinsky says: "I would not routinely recommend turmeric supplements to my patients with knee osteoarthritis. However, if a patient asked me about them, I would explain what we know and what remains uncertain about their benefits and potential harms, and help them make an informed decision."

The authors used the Trustworthiness Screening Tool developed by the Cochrane Pregnancy and Childbirth group. Similar tools have since been developed, including INSPECT-SR, which is designed to help researchers identify problematic studies that may distort evidence syntheses.



Wednesday, November 18, 2026

What the evidence really says about the Mediterranean diet and cancer risk

 Among the levers people can pull to lower their cancer risk, diet is the most daily — and the most disputed. Few dietary patterns have attracted more attention than the Mediterranean diet: abundant vegetables, fruits, legumes, whole grains, nuts, fish, and olive oil, with little red or processed meat. A narrative review published in The Innovation Nutrition weighs the epidemiological and mechanistic evidence behind its reputation, and finds a pattern that is encouraging but uneven.

The broad picture is one of inverse association. Across cohort studies and meta-analyses, higher adherence to the Mediterranean diet generally tracks with lower overall cancer risk. The signal is most consistent for colorectal and gastric cancers — plausibly, the authors note, because these tumors sit closest to the diet's main influence pathways: chronic inflammation, oxidative stress, metabolic dysregulation, gut microbiota composition, and epigenetic regulation. Individual components may contribute independently: unsaturated fatty acids, polyphenols, and dietary fiber each have proposed anti-carcinogenic roles. For other cancer sites, including prostate cancer, the evidence remains inconsistent.

The review is careful about what this evidence cannot yet say. Exposure definitions vary substantially between studies — there is no single standardized score for "Mediterraneanness" — and self-reported dietary data carry well-known measurement bias. Cancer type heterogeneity and regional differences in what people actually eat further complicate comparisons. Most fundamentally, the predominant study designs are observational, which limits causal inference: people who eat Mediterranean-style diets differ from others in many ways beyond the plate.

Geography is another boundary. The evidence base is built largely on European and American populations, whose dietary baselines, lifestyle contexts, and cancer spectra differ from those of Asia and other non-Mediterranean regions. Whether the same protective associations hold there — and what an adapted dietary pattern should look like — remains to be tested. The authors single this out as a research priority of direct relevance to cancer prevention in Asia.

Their roadmap is concrete: standardize Mediterranean diet assessment instruments; prioritize high-quality prospective cohort and interventional studies that can support causal inference; and apply multi-omics approaches to pin down which biological mechanisms — inflammatory, metabolic, microbial, or epigenetic — carry the strongest causal weight.

None of this diminishes the diet's broader appeal: the same pattern is already associated with cardiovascular and metabolic benefits, and the mechanistic plausibility for cancer is coherent. But the review's message to readers and researchers alike is that "associated with lower risk" is not yet "proven to prevent cancer" — and that the next round of evidence should come from better instruments, stronger designs, and populations far from the Mediterranean shore.


Intermittent fasting offers no additional benefits over the Mediterranean diet for reducing liver fat

A multicenter clinical trial involving 197 participants, led by the University of Granada and the Public University of Navarra, concludes that losing at least 5% of body weight is the key factor in reducing liver fat, regardless of the chosen meal schedule

A study led by the University of Granada and the Public University of Navarra has determined that, in the context of intermittent fasting, the time of day when one eats matters less than the amount of weight lost when it comes to reducing liver fat. The clinical trial, published in the journal JHEP Reports, included 197 participants aged 30 to 60 who were overweight or obese and compared three types of time-restricted eating (early, late, and self-selected windows) with a nutritional education program based on the Mediterranean diet. The results show that none of the three fasting windows produced additional reductions in liver fat compared to standard care, and that the greatest decreases were observed among those who lost at least 5% of their body weight. The research is part of the doctoral dissertation of Antonio Clavero Jimeno, a predoctoral researcher at the University Joint Institute for Sport and Health (iMUDS) at the University of Granada (UGR).

The study compared three forms of time-restricted eating (TRE), a type of intermittent fasting that limits the period during which participants can eat to specific hours of the day. Participants were randomly assigned to four groups: standard care, early fasting (approximately between 9 a.m. and 5 p.m.), late fasting (between 2 p.m. and 10 p.m.), and self-selected fasting, on average between 12:20 p.m. and 8 p.m. For 12 weeks, all participants received the same nutritional education program based on the Mediterranean diet and healthy lifestyle habits; thus, the trial evaluated whether adding any of the three fasting windows provided additional benefits.

Liver fat was quantified using magnetic resonance imaging (MRI), and liver stiffness and other liver parameters, liver enzymes, and various circulating proteins related to liver metabolism were also analyzed. Although liver fat decreased in the three groups that practiced intermittent fasting, when these changes were compared with those observed in the

usual-care group, the differences were not statistically significant. No differences were found either between having the eating window in the morning, in the afternoon, or at a freely chosen time, nor in other indicators of liver health or in the composition and diversity of the gut microbiota.

Weight Loss, a Key Factor

The study results reveal that the greatest reductions in liver fat were observed among those who lost at least 5% of their body weight—most of whom were in the intermittent fasting groups—and among individuals who already had hepatic steatosis at the start of the study.

Specifically, approximately 40 to 45% of those who practiced intermittent fasting lost at least 5% of their body weight, and reaching this threshold was associated with a significantly greater reduction in liver fat.

“The results do not suggest that intermittent fasting is ineffective, but rather that choosing an early, late, or self-selected fasting window does not appear to provide any additional benefit for liver health,” explain Manuel Dote Montero and Antonio Clavero Jimeno, the study’s first authors. For the researchers, “the most important factor seems to be choosing a strategy that facilitates clinically significant weight loss and can be sustained over time.”

A secondary analysis of a previous trial

This study is a secondary analysis of a clinical trial previously published in the journal Nature Medicine, which found that participants who practiced intermittent fasting—regardless of their eating schedule—lost, on average, between 3 and 4 kilograms more than the group that received only nutritional recommendations. In addition, early fasting—which in many cases is equivalent to skipping dinner in Spain—showed specific benefits regarding certain indicators of glucose regulation.

The study is part of the doctoral dissertation of Antonio Clavero Jimeno, a predoctoral researcher at iMUDS, who led the study alongside Manuel Dote Montero, currently a postdoctoral researcher at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in the United States. The research is being conducted by the PROFITH CTS-977 research group at the University of Granada’s iMUDS, led by Professor Jonatan Ruiz Ruiz, in collaboration with ibs.GRANADA, the San Cecilio University Clinical Hospital (HUCSC), and the Virgen de las Nieves University Hospital in Granada, as well as the research group led by Dr. Idoia Labayen, a professor at the Public University of Navarra, together with the CIBER on Obesity (CIBEROBN), the CIBER on Frailty and Healthy Aging (CIBERFES), and the CIBER on Liver and Digestive Diseases.

My latest supplement

 Quercetin w/ Bromelain


Quercetin is the major polyphenolic flavonoid that belongs to the class called flavanols. It is found in many foods, such as green tea, cranberry, apple, onions, asparagus, radish leaves, buckwheat, blueberry, broccoli, and coriander. 

Quercetin has antioxidant, anti-inflammatory, cardioprotective, antiviral, and antibacterial effects. It is found to be beneficial against cardiovascular diseases, cancer, diabetes, neuro-degenerative diseases, allergy asthma, peptic ulcers, osteoporosis, arthritis, and eye disorders. In pre-clinical and clinical investigations, its impacts on various signaling pathways and molecular targets have demonstrated favorable benefits for the activities mentioned above, and some global clinical trials have been conducted to validate its therapeutic profile.

Bromelain is promoted as a dietary supplement for a variety of purposes including postoperative pain after wisdom tooth extraction, sinusitis, osteoarthritis, and exercise-induced muscle soreness.


Also see:

https://healthnewsreport.blogspot.com/2026/07/my-latest-supplement.html

https://healthnewsreport.blogspot.com/2026/04/5-more-of-my-supplements.html

https://healthnewsreport.blogspot.com/2026/04/some-of-my-supplements.html



Chronic loneliness increases dementia risk by 38%, but occasional loneliness is harmless

 

A new study that has tracked people over the course of 30 years, demonstrates how only chronic, persistent loneliness is strongly linked with dementia.

The findings are published today in the peer-reviewed journal Aging & Mental Health. They emerge after a team of researchers from the Université de Bordeaux assessed thousands of people aged 65 and over, for three types of loneliness – ‘never’, ‘occasional’ and ‘chronic’ – repeatedly over the course of eight years.

The individuals who experienced chronic loneliness had a 38% higher risk of developing dementia compared to those who never felt lonely. Importantly, however, occasional loneliness showed no significant association with increased dementia risk.

The outcomes of the paper challenge the assumption that any experience of loneliness poses equal danger to cognitive health, explains co-author Karine Pérès, a Senior Researcher at the Bordeaux Population Health Centre (based at the university).

“This distinction is critical,” says Karine, who specialises in the epidemiology of ageing, with a particular focus on the impact of loneliness on health.

“While most people experience loneliness at some point in their lives, it is when loneliness becomes chronic and persistent that it may increase the risk of developing dementia.”

The paper arrives at a critical time, as both loneliness and dementia represent escalating global health challenges. The World Health Organization (WHO) has identified a ‘loneliness epidemic’, with 25% of older adults socially isolated and 20-34% reporting loneliness. Dementia has been labelled by WHO as a ‘global health threat’, with cases projected to reach 150 million worldwide by 2050.


How the study was conducted

To better understand how the two are linked – and specifically to look at whether persistent, long-term loneliness impacts dementia (rather than all loneliness) – the Bordeaux research team assessed data from a French study that followed 3,777 older adults from 1988 to 2018.

The Bordeaux researchers created a system to identify loneliness trajectories over eight years and classify participants into the three loneliness groups:

  • Never lonely: No loneliness reported at any visit (48.3% of participants)
  • Occasional loneliness: Loneliness reported at one or two visits (34.4%)
  • Chronic loneliness: Loneliness reported at three or four visits (17.3%)

During a second phase they then assessed the risk of developing dementia in the next twenty years, according to these previously defined loneliness groups.

They compared the three groups to determine whether people with different patterns of loneliness over the initial eight years were more likely to develop dementia than others. Dementia diagnoses were based on standardized medical criteria.

By 1995-96, the start of phase two, 1,540 participants remained eligible.

Among the 1,540 eligible participants, 36.4% (560) of participants developed dementia.

The dementia incidence rates varied significantly across the three loneliness groups, ranging from 33.1% for the individuals from the ‘never’ lonely group to 49.1% for those with chronic loneliness.

  • For those who were categorised as ‘never’ lonely, 33.1% went on to develop dementia (246 out of 743 participants)
  • 34.5% of the occasional lonely group developed dementia (183 out of 530 participants)
  • The chronic loneliness group showed a notably higher dementia incidence rate –49.1% developed dementia (131 out of 267 participants)
     

Why chronic loneliness matters

“The previous research suggests several mechanisms through which persistent loneliness may accelerate cognitive decline,” adds Karine.

“Chronic loneliness triggers sustained inflammation through prolonged activation of stress and immune pathways. It’s also associated with physical inactivity and poor diet, contributing to cardiovascular disease and diabetes—both dementia risk factors. Additionally, lack of social interactions limits cognitive stimulation, while unresolved social stress leads to an accumulation of biological wear and tear over time.”
 

Beyond living alone and impact for policy

Another important revelation from the study was that individuals living in couples or family settings may still experience chronic loneliness. Within the sample, 29.6% of those chronically lonely did not live alone.

“It shows this vulnerability may also stem from unsatisfying relationships, caregiving burdens, or lack of meaningful activities,” explains lead author Yvanna Simon.

“Healthcare professionals, social workers, and policymakers should not exclusively focus on living arrangements as a proxy for social risk, but should also incorporate subjective experiences of connection and loneliness.”


A call to action

The researchers advocate for comprehensive approaches to address chronic loneliness – with an aim of tackling potential, future dementia.

Among recommendations include increased referrals from those in healthcare for social activities; more inclusive, mixed-aged public spaces; and greater loneliness screening within healthcare settings.

“As some situations of loneliness are potentially preventable or reversible, it may represent a critical actionable target for interventions aimed at promoting healthy cognitive aging, preserving autonomy, and improving quality of life in later adulthood,” the paper concludes.

A limitation of the study, includes its reliance on a single question to measure loneliness rather than a comprehensive assessment; meaning it could not capture important details like the quality of participants’ relationships or whether they had meaningful activities in their lives.

However, the paper has significant strengths such as the steps taken to ensure reliable findings, including excluding anyone with early cognitive decline. The study also adjusted for age, sex, education, living situation, health status, medications, and depression. The researchers also recorded deaths to account for competing health risks.

Tuesday, November 17, 2026

Daily iron supplements reduce iron deficiency anemia in children and adolescents

 

Giving children and adolescents a daily iron tablet significantly reduces the risk of iron deficiency anaemia with little to no effect on several common illnesses, according to a Cochrane review of 114 studies involving more than 50,000 participants.

Iron deficiency occurs when the body lacks enough iron for its needs. These include making haemoglobin, the protein in red blood cells that carries oxygen from the lungs to the rest of the body. Left untreated, it leads to iron deficiency anaemia.

Iron supplementation is the standard of care for the prevention and treatment of anaemia in many parts of the world particularly for adolescents and women. Previous evidence has pointed to the benefits of iron supplementation for improving iron deficiency anaemia in children. However, current World Health Organization guidelines, last updated in 2016, emphasize the gap in evidence on the long-term effects.

Led by researchers from Cornell Joan Klein Jacobs Center for Precision Nutrition and Health at Cornell University, the review included 114 studies with over 50,000 children and adolescents, looking at the effects of daily oral iron, alone or with folic acid or when other vitamins and minerals were added. Many of the studies were conducted in Asia and focused on children under five years of age.

Daily iron reduces the risk of iron deficiency anaemia

Findings from this review demonstrate that iron alone probably reduces iron deficiency anaemia compared with no intervention or placebo. Iron with folic acid probably reduces it too, although this finding rests on a single study, and iron with other vitamins and minerals also may reduce it. For anaemia and iron deficiency more broadly, there is some evidence that iron may be useful for reducing both.

Iron alone had no effect on how tall a child is or how much they weigh, compared with other children of the same age and sex. It also had no effect on several common illnesses, such as cough, fever or respiratory illness, and iron with folic acid makes little to no difference to diarrhoea or respiratory illness. Findings for other combinations ranged from moderate to very low certainty.

“Iron deficiency remains one of the most common nutritional problems affecting children worldwide,” says first author Dr Kripa Rajagopalan. “Our review shows that daily iron supplements do what they are meant to do, which is reduce iron deficiency anaemia, without any measurable impact on the common illnesses parents and health workers worry about.”

Side effects are mostly mild, but evidence is uncertain

The evidence on side effects was unclear for some outcomes. Iron may increase stool discolouration. Iron alone may make little to no difference to vomiting or diarrhoea, and the effect on constipation is very uncertain. Iron combined with other vitamins and minerals probably increases vomiting compared with the same supplement without iron.

Senior author Dr Saurabh Mehta explains: “While the evidence base supports the use of daily iron supplements where needed, some adverse effects do occur. Stool discolouration and, in some formulations, vomiting were more common with iron, and the certainty of evidence for several outcomes, including anaemia and iron deficiency themselves, was low or very low.”

Anaemia remains a major global burden for young children

Anaemia affects an estimated 874 million children and women worldwide; the greatest burden is seen among young children, with 40% of children younger than five years affected in 2019. Approximately half of these cases are due to iron deficiency. Reducing anaemia is a key goal of the 2030 Global Strategy for Women’s, Children’s and Adolescents’ Health.

“These findings give decision-makers a stronger evidence base for guidance on iron supplementation in children and adolescents,” says co-author Dr Julia L. Finkelstein. “The data supports continued use of iron supplementation where iron deficiency is a concern.”

The authors stress that the findings support iron supplementation but should not be read as meaning every child or adolescent needs daily iron supplements. They should be interpreted in light of individual nutritional needs, the prevalence of iron deficiency and anaemia, and the formulation of the supplement.

Friday, November 13, 2026

An erratic sleep schedule harming your mental health

 

Depression and anxiety may be the price you pay for going to bed and waking up at inconsistent times


People with irregular sleep-wake schedules may experience more severe symptoms of anxiety, depression, and even loneliness, according to a large study led by UC San Francisco and UC San Diego.  

Although prior sleep research has largely focused on sleep duration and sleep quality, this study examined sleep regularity — how consistently people followed the same sleep-wake patterns each day — using months of data from wearables. 

The study was published in Scientific Reports on Nov. 12.  

“Regular sleep and wake time help keep circadian rhythms aligned,” said senior author Ashley Mason, PhD, of the UCSF Department of Psychiatry and Behavioral Sciences. “Irregular sleep-wake timing may weaken circadian alignment, which is associated with depression and other mental health disorders.” 

Irregular sleep schedules can also disrupt the timing of light exposure, meals, exercise, and social activity, all of which help regulate the circadian rhythm, noted Mason, who is also affiliated with the UCSF Osher Center for Integrative Health.  

In this study, researchers analyzed data from approximately 23,000 participants who were enrolled in TemPredict, a study launched in 2020 to investigate whether data from wearables could help identify COVID-19 before people recognized symptoms.  

Participants contributed an average of 154 days of sleep data, which allowed researchers to examine sleep regularity over time. They also created a “typical week” snapshot to compare their findings with previous, much shorter studies on sleep regularity. They discovered that associations between sleep and mental health were stronger with the longer-term data. 

The participants’ average age was 46 and just under half were women. They wore a smart ring that uses sensors to detect movement and measure vital signs. The smart ring used this data to estimate when they fell asleep and woke up. Researchers were then able to calculate each participant’s Sleep Regularity Index (SRI), ranging from 0 to 100, with higher scores indicating more consistent sleep patterns. 

Worsening depression, anxiety tied to progressive sleep irregularity 

Participants’ depression, anxiety, and loneliness were assessed by a monthly self-reported survey. Overall, less regularly timed sleep correlated with greater depression and anxiety. 

In the long-term analysis, participants with few symptoms of depression or none at all had an average SRI of 84, compared with 83 for those with mild depressive symptoms, 81 for moderate symptoms, and 75 for severe symptoms.   

Participants with normal levels of anxiety had an average SRI of 84, compared to 79 for those with severe anxiety. Participants with elevated loneliness also had less regular sleep-wake schedules.  

“Someone with an SRI of 84 might go to bed and wake up roughly an hour earlier or later than the previous day, on average,” said first author Severine Soltani, PhD, formerly of the Bioinformatics and Systems Biology graduate program at UC San Diego. “For someone with an SRI of 75, that shift in sleep schedule might be closer to an hour and a half.” 

Mason said the association between poor sleep and poor mental health could be codirectional: Irregular sleep could also be explained as a symptom of poor mental health. “Other longitudinal research provides some reason to think that irregular sleep may come first and contribute to later poor health, rather than being solely a consequence of it.” 

The authors say future research should test whether helping people establish more regular sleep schedules can improve mental health.